Prospective Study to Determine Impact of Early Palliative Care Consult on Quality of Life (QOL), Cancer Related Symptoms In Advanced Lung Cancer Patients: Thoracic Pilot Project

Sponsor
M.D. Anderson Cancer Center (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT02459002
Collaborator
(none)
209
1
122.4
1.7

Study Details

Study Description

Brief Summary

The goal of this study is to learn about the quality of life (QOL) in participants with advanced lung cancer.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: QOL Questionnaire
  • Behavioral: Caregiver Satisfaction Questionnaire

Detailed Description

Advanced lung cancer (ALC) will be assessed for participant outcomes in a sample which is prior initiation of palliative consultation and in a sample after the initiation of early palliative consultation.

Study goals are:
  1. To determine the differences in participant outcomes including quality of life (QOL); symptom distress [Edmonton symptom assessment scale (ESAS)] and caregiver outcomes [Zarit Burden Interview , Hospital Anxiety and Depression scale(HADS) and FAMCARE] at week 12 in advanced lung cancer (ALC) patients receiving early palliative care consultation versus those who don't.

  2. Identify the cellular, molecular, and immune basis for the development of symptoms in patients with ALC.

Study Design

Study Type:
Observational
Actual Enrollment :
209 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Prospective Study to Determine Impact of Early Palliative Care Consult on Quality of Life (QOL), Cancer Related Symptoms In Advanced Lung Cancer Patients
Actual Study Start Date :
Jul 18, 2012
Anticipated Primary Completion Date :
Sep 30, 2022
Anticipated Study Completion Date :
Sep 30, 2022

Arms and Interventions

Arm Intervention/Treatment
NSCLC - Current Palliative Care Referral Practices

Early palliative consultation impact assessment via questionnaires during a regularly scheduled clinic visit or during inpatient stay.

Behavioral: QOL Questionnaire
Participant outcomes assessed with survey
Other Names:
  • survey
  • Primary Caregiver

    Caregiver satisfaction with quality of care and early palliative consultation impact assessed via questionnaires during a regularly scheduled clinic visit or during inpatient stay.

    Behavioral: Caregiver Satisfaction Questionnaire
    Caregiver satisfaction with quality of care assessed with surveys
    Other Names:
  • survey
  • NSCLC - After Early Palliative Care Consult System

    Palliative consultation impact assessment via questionnaires during a regularly scheduled clinic visit or during inpatient stay.

    Behavioral: QOL Questionnaire
    Participant outcomes assessed with survey
    Other Names:
  • survey
  • Outcome Measures

    Primary Outcome Measures

    1. Participants' QOL Assessments [Baseline till participant death or end of follow-up period, assessed every 4 weeks for approximately 12 weeks]

      Impact of early palliative consultation (defined as palliative consultation within 8 weeks of initial advanced cancer diagnosis) on participant outcomes including improvement QOL [FACT-L trial outcome index [TOI] score)]. QOL assessed with FACT-L instrument, widely used to assess QOL of advanced NSCLC. FACT-L consists of 4 general & 1 lung cancer symptom-specific subscale. General subscales include physical well-being (PWB; seven items), social/family well-being (seven items), emotional well-being (five items), and functional well-being (FWB; seven items). The seven-item lung cancer subscale (LCS) assesses symptoms commonly reported by lung cancer patients (e.g., shortness of breath, loss of weight, tightness in chest). The 21-item TOI (Trial Outcome Index) is derived by adding PWB, FWB, and LCS scores. All FACT-L items are rated on five-point scales ranging from 0 for "not at all" to 4 for "very much." Higher scores are representative of better QOL or fewer symptoms.

    Secondary Outcome Measures

    1. Caregiver Outcomes: FAMCARE Scale [Baseline till participant death or end of follow-up period, assessed every 4 weeks for approximately 12 weeks]

      Caregiver satisfaction with quality of care assessed with FAMCARE validated 12-item survey, which measures the degree of satisfaction with health care in terms of information provided, availability of care, physical individual with advanced cancer care, and psychological care.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Have a diagnoses of advanced NSCLC (defined as locally advanced or metastatic)

    2. Have no clinical evidence of cognitive failure, as evidenced by a Memorial Delirium Assessment Score of less than or equal to 7 of 30 at the time of consent.

    3. Be at least 18 years of age.

    4. Be able to understand the description of the project and give written informed consent.

    5. Plan to receive their cancer treatment at MD Anderson Cancer Center.

    6. Individuals with advanced cancer who are able to identify a primary caregiver who also agrees to participate (in person or by telephone) in the study. A caregiver will be defined as a spouse, first degree relative, or other person designated by the patient as providing direct assistance to the patient in his/her activities of daily living.

    Exclusion Criteria:
    1. Patients to be excluded from the study will be those unable to complete the baseline assessment forms or to understand the recommendations for participation in this project.

    2. Patients seen at the Thoracic center at UT MD Anderson Cancer Center after 8 weeks of the initial diagnosis (first cohort only - patients using the current Palliative Care referral practices prior to the implementation of the early palliative care program).

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Texas MD Anderson Cancer Center Houston Texas United States 77030

    Sponsors and Collaborators

    • M.D. Anderson Cancer Center

    Investigators

    • Study Chair: Siriam Yennu, MD, M.D. Anderson Cancer Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    M.D. Anderson Cancer Center
    ClinicalTrials.gov Identifier:
    NCT02459002
    Other Study ID Numbers:
    • 2012-0405
    • NCI-2019-02352
    First Posted:
    Jun 1, 2015
    Last Update Posted:
    Feb 28, 2022
    Last Verified:
    Feb 1, 2022
    Keywords provided by M.D. Anderson Cancer Center
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 28, 2022